share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 18 04:38
Summary by Moomoo AI
赛生药业控股有限公司於2024年4月17日宣布，根據香港《公司收購及合併守則》規則22，執行人員Lai Chin Hung透過協議安排進行了一宗私有化交易。該交易涉及購入5,000股赛生药业股份，每股價格為$0.0000，交易完成後Lai Chin Hung持股數目增至12,967股，佔公司同類別證券的0.0021%。此次股份變動源於公司首次公開發售後受限股份單位計劃，於2024年4月5日將股份獎勵歸屬於Lai Chin Hung。
赛生药业控股有限公司於2024年4月17日宣布，根據香港《公司收購及合併守則》規則22，執行人員Lai Chin Hung透過協議安排進行了一宗私有化交易。該交易涉及購入5,000股赛生药业股份，每股價格為$0.0000，交易完成後Lai Chin Hung持股數目增至12,967股，佔公司同類別證券的0.0021%。此次股份變動源於公司首次公開發售後受限股份單位計劃，於2024年4月5日將股份獎勵歸屬於Lai Chin Hung。
Sai Seng Pharmaceutical Holdings Limited announced on 17 April 2024 that under Rule 22 of the Hong Kong Code of Companies, Lai Chin Hung, Executive Officer Lai Chin Hung has entered into a privatization transaction through a contractual arrangement. The transaction involves the purchase of 5,000 shares of Sai Seng Pharmaceuticals at a price of $0.0000 per share and the number of Lai Chin Hung shares upon completion of the transaction increased to 12,967 shares representing 0.0021% of the company's class securities. This share change stems from the Company's initial public offering of a limited share unit plan that will attribute the share award to Lai Chin Hung on April 5, 2024.
Sai Seng Pharmaceutical Holdings Limited announced on 17 April 2024 that under Rule 22 of the Hong Kong Code of Companies, Lai Chin Hung, Executive Officer Lai Chin Hung has entered into a privatization transaction through a contractual arrangement. The transaction involves the purchase of 5,000 shares of Sai Seng Pharmaceuticals at a price of $0.0000 per share and the number of Lai Chin Hung shares upon completion of the transaction increased to 12,967 shares representing 0.0021% of the company's class securities. This share change stems from the Company's initial public offering of a limited share unit plan that will attribute the share award to Lai Chin Hung on April 5, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more